Interview with Charles Jaffe, MD, PhD of HL7
Q: What need is HL7 addressing?
A: For more than three decades, HL7 has provided the platform to enable global health data interoperability. This is more important than ever, as the cost of healthcare has increased exponentially, and the complexity of clinical evidence has grown to an almost unmanageable state.
read moreInterview with Eden Haverfield of Invitae
Q: What need is Invitae addressing?
A: Our mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae is uniquely positioned to answer some of life’s most serious and complex questions with the highest quality genetics and at an affordable price.
read moreCall by Ralph Snyderman (Duke U.) for Big Changes to Get to the Next Level of Precision Medicine
Beyond next-generation gene sequencing and developing diagnostic tools and targeted therapies, theoverall approach to clinical care has to be re-envisioned to fulfill the promise of precision medicine. Care must move from sporadic treatment of episodic disease (a reactive mode) to predicting disease and then acting to prevent and mitigate it (a proactive mode).
read moreInterview with William Hearl of Immunomic Therapeutics, Inc.
Q: What need is Immunomic Therapeutics, Inc. addressing?
A: Immunomic Therapeutics’ nucleic acid vaccines have the potential to utilize the body’s natural biochemistry to develop a broad immune response, including antibody production, cytokine release and critical immunological memory.
read moreInterview with Ralph Snyderman of Duke University
Q: What are some of the critical contributions that academic institutions and medical centers are making to implement and accelerate precision medicine?
A: Over the past decade, the field of precision medicine has created technologies enabling far more personalized and effective health care delivery. Many of the most dramatic advances have come in the field of oncology but targeting care to the needs of the individual is rapidly achieving broader applications.
read moreInterview with Catherine Reinis Lucey of UCSF
Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?
A: My work involves designing, implementing and studying innovations in medical education that allow our medical schools to fulfill our social contract to improve the health of our communities and reduce the suffering of our patients.
read moreInterview with Gunnar Carlsson of Ayasdi
Q: What need is Ayasdi addressing?
A: Ayasdi is pioneering the application of artificial intelligence to value-based care by targeting two of the most complex problems in healthcare: population risk stratification and clinical variation management.
read moreInterview with Nikole Kimes of Siolta Therapeutics
Q: What need is Siolta Therapeutics addressing?
A: Chronic diseases, including inflammatory diseases such as asthma, now represent the leading cause of mortality and morbidity worldwide.
read moreNote from Dr. Patrick Conway, President & CEO, Blue Cross and Blue Shield NC to PMWC
VC activity is booming in healthcare, with second quarter drawing in $5.1 billion in capital. That is 22% of the total $23 billion raised by all VC-based companies in the U.S., according to latest Pricewaterhouse Coopers quarterly report.
read moreInterview with Atul Sharan, Co-founder and CEO, CellMax Life
Q: CellMax has developed non-invasive blood tests based on Circulating tumor cells CTC. How do you see these tests being adopted clinically?
A: Survival rates are greater than 90% for cancers that are detected at an early stage.
read more
